Cargando…
Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
BACKGROUND: Lenvatinib is an oral, multitargeted, tyrosine kinase inhibitor under clinical investigation in solid tumors. In vitro evidence indicates that lenvatinib metabolism may be modulated by ketoconazole, an inhibitor of CYP3A4 and p-glycoprotein. METHODS: In this Phase I, single-center, rando...
Autores principales: | Shumaker, Robert, Aluri, Jagadeesh, Fan, Jean, Martinez, Gresel, Thompson, Gary A, Ren, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467237/ https://www.ncbi.nlm.nih.gov/pubmed/26097795 http://dx.doi.org/10.1002/cpdd.140 |
Ejemplares similares
-
Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
por: Shumaker, Robert C., et al.
Publicado: (2014) -
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
por: Shumaker, Robert, et al.
Publicado: (2020) -
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
por: Hong, David S., et al.
Publicado: (2015) -
Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021) -
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)